| 亓秉超,胡 朗,邱继欢,李春雨,季乐乐,李 妍.人参皂苷Rb1通过上调PGC-1α缓解糖尿病心肌病[J].现代生物医学进展英文版,2020,(1):19-23. |
| 人参皂苷Rb1通过上调PGC-1α缓解糖尿病心肌病 |
| Ginsenoside Rb1 Alleviates Diabetic Cardiomyopathy through Up-regulating PGC-1α |
| Received:June 27, 2019 Revised:July 29, 2019 |
| DOI：10.13241/j.cnki.pmb.2020.01.004 |
| 中文关键词: 人参皂苷Rb1 糖尿病心肌病 PGC-1α 线粒体ROS |
| 英文关键词: Ginsenoside Rb1 Diabetic cardiomyopathy PGC-1α Mitochondrial ROS |
| 基金项目:国家自然科学基金项目（81570252）；国家自然科学基金项目（81770369） |
| Author Name | Affiliation | E-mail | | QI Bing-chao | Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710000, China | 1040132671@qq.com | | HU Lang | Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710000, China | | | QIU Ji-huan | Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710000, China | | | LI Chun-yu | Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710000, China | | | JI Le-le | Experimental Teaching Center of Basic Medicine, Fourth Military Medical University, Xi'an, Shaanxi, 710000, China | | | LI Yan | Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710000, China | |
|
| Hits: 1207 |
| Download times: 607 |
| 中文摘要: |
| 摘要 目的：研究人参皂苷Rb1对糖尿病心肌病的治疗作用并阐明其分子机制。方法：采用腹腔注射链脲佐菌素的方法，建立糖尿病心肌病动物模型。将小鼠分为3组：WT组，DM组，DM+Rb1组。超声心动图分析小鼠心功能；Western blot分析PGC-1α、cleaved caspase-3、bcl-2等蛋白表达；MitoSOX染色分析线粒体ROS含量；透射电镜分析线粒体数目。结果：与WT组相比，DM组小鼠心功能显著下降（LVEF，P＜0.01），PGC-1α表达下调（P＜0.01），线粒体数目减少（P＜0.01）；而Rb1处理后，显著改善了DM小鼠心功能（LVEF，P＜0.01），恢复了PGC-1α表达（P＜0.05），增加了线粒体数目（P＜0.05）。同时，Rb1处理后，减少了糖尿病小鼠心肌线粒体ROS产生（P＜0.01），恢复了bcl-2蛋白表达（P＜0.01），降低了cleaved caspase-3蛋白表达（P＜0.01），从而减少了高糖引起的细胞凋亡（P＜0.05）。而siPGC-1α处理后，阻断了Rb1的上述作用。结论：人参皂苷Rb1通过上调PGC-1α改善糖尿病小鼠心功能，缓解糖尿病心肌病。其机制可能与人参皂苷Rb1降低心肌线粒体ROS产生并减少心肌细胞凋亡有关。 |
| 英文摘要: |
| ABSTRACT Objective: To study the therapeutic effect of ginsenoside Rb1 on diabetic cardiomyopathy and to elucidate its molecular mechanism. Methods: An animal model of diabetic cardiomyopathy was established by intraperitoneal injection of streptozotocin. Mice were divided into 3 groups: WT group, DM group and DM+Rb1 group. Cardiac function of mice was analyzed by echocardiography. Expression of PGC-1α, cleaved caspase-3 and bcl-2 was analyzed by Western blot. Mitochondrial ROS content was analyzed by MitoSOX staining. The number of mitochondria was analyzed by electron microscopy. Results: Compared with the WT group, the cardiac function of the DM group was significantly decreased (LVEF, P<0.01). Expression of PGC-1α was down-regulated (P<0.01). The number of mitochondria was decreased (P<0.01). After Rb1 treatment, the cardiac function of DM mice was significantly improved (LVEF, P<0.01). PGC-1α expression was restored (P<0.05). The number of mitochondria was increased (P<0.05). At the same time, Rb1 treatment reduced myocardial mitochondrial ROS production (P<0.01), restored bcl-2 protein expression (P<0.01), decreased cleaved caspase-3 protein expression (P<0.01), and decreased Apoptosis induced by high glucose (P<0.05). After treatment with siPGC-1α, the above protective effects of Rb1 were blocked. Conclusion: Ginsenoside Rb1 improves cardiac function and alleviates diabetic cardiomyopathy by up-regulating PGC-1α. The mechanism may be related to the reduction of myocardial mitochondrial ROS production and reduction of cardiomyocyte apoptosis by ginsenoside Rb1. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
